Cramer Remix: This group's about to be hammered

Cramer Remix: This group's about to be hammered · CNBC

Everywhere Jim Cramer looked on Wednesday he saw the same theme resonate throughout the market — guilty until proven innocent.

"The presumption at the moment is that if a company is at all suspect, its stock is either guilty or will be found guilty by association," the "Mad Money" host said. (Tweet This)

That means Cramer expects more selling in drugs, entertainment, oil and restaurant stocks. If you're a trader, then it's time to join the fray.

But for investors, Cramer had a stern warning when he said, "Don't play the uptrend that's running higher. Play the downtrend that's running out of steam."

He recommended waiting three to five more days for the punishment to play out, and then buy the stocks that have been crushed. At that point, the best-of-breed stocks may need a few more days of recidivism before bottoming but will prove to be strong stocks for any portfolio.

Read More Cramer: Don't you dare play the uptrend

Whole Foods Market (NASDAQ: WFM) was hit hard in after-hours trading on Wednesday after reporting a lackluster third quarter. Jim Cramer was left wondering how this company plans to fend off the competition and turn things around.

The company delivered per share earnings of 30 cents for third quarter, excluding a couple of one-time items, when Wall Street was looking for more than 34-cents. It also had weaker-than-expected revenues and negative same-store sales growth. Additionally, management's guidance for 2016 was below what analysts were expecting.

To find out more about the initiatives that Whole Foods has in store to turn things around, Cramer spoke with co-CEO Walter Robb.

"It was a tough quarter, and we own it … But any way you slice it, they are not what we want. They are not what we expect, and we outlined today the steps we are going to take moving forward," Robb said. (Tweet This)

Read More Whole Foods co-CEO: Was a tough quarter, we own it

Washington gave investors a big gift to investors on Wednesday, and in a few days when the heat blows over, Cramer wants them to take it.

Allergan is the pharmaceutical roll-up formerly known as Actavis, which is currently in talks to be taken over by Pfizer. It reported a strong quarter on Wednesday, with a 30-cent earnings beat from a $3.18 basis and higher than expected revenue that rose 90 percent year-over-year.

However instead of rallying, the stock closed the day in the red. This was because Democrats in the House of Representatives announced a newly formed Affordable Drug Price Tasking Force to fight the rise in drug prices. It sent many drug stocks spiraling, even though Allergan is nothing like Valeant.